Abstract
The increasing frequency of ventilator-associated pneumonia (VAP) caused by colistin-only susceptible (COS) gram-negative bacteria (GNB) is of great concern. Adjunctive aerosolized (AS) colistin can reportedly increase alveolar levels of the drug without increasing systemic toxicity. Good clinical results have been obtained in patients with cystic fibrosis, but conflicting data have been reported in patients with VAP.
Lingua originale | English |
---|---|
pagine (da-a) | 1768-1775 |
Numero di pagine | 8 |
Rivista | Chest |
Volume | 144 |
DOI | |
Stato di pubblicazione | Pubblicato - 2013 |
Keywords
- VAP
- colistin